Dossier assessment
Erdafitinib (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Erdafitinib (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Erdafitinib (urothelial carcinoma) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with unresectable or metastatic urothelial carcinoma, harbouring susceptible fibroblast growth factor receptor 3 genetic alterations after prior therapy with a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting
- and for whom cisplatin-containing chemotherapy is suitable and who have not yet received such therapy; second-line treatment: added benefit not proven
- and for whom cisplatin-containing chemotherapy is unsuitable; second-line treatment: added benefit not proven
- and after prior platinum-containing chemotherapy, and for whom chemotherapy is suitable; third-line treatment: added benefit not proven
Project details
- Project no.
- A25-01
- Commission
- Commission awarded on 02.01.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-01_en